Drugs / Glycerin
Glycerin
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PROCALAMINE | — | 1982-05-06 | fda.gov ↗ |
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06375343 | Jan 2026 → Jan 2027 expected | dry eye syndrome | Laboratorios Sophia S.A de C.V. | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00243711 | Sep 2005 → Apr 2006 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03197922 | Oct 2017 → Nov 2022 | autism spectrum disorder, bowel dysfunction | Emory University | Completed | No outcome recorded |
| Phase 44 trials · 2 missed | ||||||
| Phase 4 | NCT05821309 | Jun 2023 → Jul 2026 overdue | constipation disorder | Indiana University | Recruiting | No outcome recorded |
| Phase 4 | NCT03355326 | Oct 2017 → Oct 2020 | gastroschisis | Indiana University | Terminated | Missed primary Stop: Enrollment |
| Phase 4 | NCT02435069 | Feb 2016 → Mar 2017 | neurogenic bowel | Nemours Children's Clinic | Completed | Missed primary |
| Phase 4 | NCT00987727 | Nov 2009 → Jul 2010 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT05660681 | Dec 2022 → Aug 2023 | dry eye syndrome | Calm Water Therapeutics LLC | Completed | No outcome recorded |
| — | NCT02383758 | Feb 2015 → Jan 2017 | autism spectrum disorder, bowel dysfunction | Emory University | Completed | No outcome recorded |
| — | NCT01799629 | Mar 2013 → Dec 2022 | — | King Faisal Specialist Hospital & Research Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00681265 | Jun → Aug 2008 | dry eye syndrome | Calm Water Therapeutics LLC | Completed | No outcome recorded |
| — | NCT00514852 | Oct 2007 → Jan 2008 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| — | NCT00544713 | Sep 2007 → Jun 2008 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Comparator or background therapy12 trials | ||||||
| Phase 4 | NCT07676084 Comparator | Jun → Oct 2026 expected | dry eye syndrome | Andover Research Eye Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT07342413 Comparator | Feb → May 2026 overdue | vein disorder | Goldman, Butterwick, Fitzpatrick and Groff | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06491394 Comparator | Nov 2024 → Mar 2025 | myopathy | Aswan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02117687 Comparator | May 2014 → Jan 2015 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02120079 Comparator | Feb 2014 → Apr 2017 | dry eye syndrome | Tufts Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00938704 Comparator | Jun 2009 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00756678 Comparator | Sep 2008 → Aug 2009 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| — | NCT05723731 Background | Jan → Jul 2023 | constipation disorder | Air Force Military Medical University, China | Terminated | No outcome recorded |
| — | NCT02153606 Comparator | Jan 2015 → Jun 2016 | — | McMaster University | Unknown | No outcome recorded |
| — | NCT02149407 Comparator | May 2014 → May 2016 | — | King Saud Medical City | Unknown | No outcome recorded |
| — | NCT01746511 Comparator | Jul 2012 → Sep 2013 | hyperbilirubinemia | University of Rochester | Completed | No outcome recorded |
| — | NCT00932477 Comparator | Aug → Sep 2009 | dry eye syndrome | Allergan | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glycerin | “Soothe Tired Eyes Lubricant Eye Drop (Bausch & Lomb Inc.) is a preserved artificial tear which is used to relieve the dryness of the eye and to prevent further irritation. Its...” NCT02120079 ↗23“Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.” NCT05723731 ↗ “Propylene glycol 0.3% - Polyethylene glycol 400 0.5% - Glycerin 0.2%. Ophthalmic solution.” NCT06375343 ↗ “Carboxymethylcellulose and Glycerin” NCT00756678 ↗ |
| Known as | Glycerin and Polysorbate 80 based artificial tear | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00932477 ↗ |
| Known as | USP Glycerin | “USP Glycerin was titrated in 5 mL increments so as not to exceed 50 mL daily.” NCT02435069 ↗ |
| Modality | Other / unclassified | “Carboxymethylcellulose and Glycerin based artificial tear” NCT00544713 ↗ |
| Route | Other | “1 to 2 drops into each eye as needed but at least twice daily” NCT00514852 ↗ |